MyoKardia begins dosing in phase 2 HCM trial of Mavacamten

This article was originally published here

MyoKardia has started dosing in its phase 2 MAVERICK-HCM clinical trial of mavacamten, the company’s oral, allosteric modulator of cardiac myosin mavacamten candidate in symptomatic non-obstructive hypertrophic cardiomyopathy patients.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply